Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EBI3/IL35 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EBI3 Recombinant Protein (ECD-Fc) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed. |
View EBI3 Products |
| Antigen | IL35 Heterodimer Protein (EBI3/IL12A) Co-expressed active heterodimer, sequence verified, native glycosylation patterns. |
View IL35 Products |
| Gene Delivery | EBI3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View EBI3 Products |
| Benchmark Ab | Anti-EBI3 Recombinant Antibody Sequence-derived from clinical benchmarks (e.g., BMS-986416 analog). |
View EBI3 Products |
| Validator | EBI3 siRNA Set Target-specific knockdown verification. |
View EBI3 Products |
| Related Target A | IL12A IL-35 heterodimerization partner (p35 subunit) crucial for assembly validation. |
View IL12A Products |
| Related Target B | IL27 Shares the EBI3 subunit (EBI3/p28); critical for off-target and selectivity screening. |
View IL27 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability (EBI3/IL12A) | HEK293 co-expressed heterodimeric proteins with optimized linker conformation. |
| Selectivity Counter-Screening (vs. IL-27) | Recombinant IL-27 and monomeric EBI3 proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live EBI3/IL35 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EBI3/IL35 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific constructs and combination therapies designed to reprogram the cold tumor microenvironment (TME). As first-generation therapies reach clinical trials, the next wave of R&D is targeting precise heterodimer-specific epitopes to avoid off-target cross-reactivity with other IL-12 family cytokines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Bristol Myers Squibb, Elpiscience | Advanced Solid Tumors, NSCLC | Neutralization Assay (Requires stable, correctly folded IL-35 heterodimer) |
| Bispecific Antibody | Preclinical Biotechs | Refractory Tumors (PD-1 resistant) | Dual-Target Binding ELISA (Requires high-purity EBI3 and PD-L1 proteins) |
| Recombinant Protein / Agonist | Academic Institutes | Autoimmune Diseases (MS, SLE) | Treg Activation Assay (Requires endotoxin-controlled bioactive IL-35) |